What is Citius Oncology, Inc.'s interest expense?

Citius Oncology, Inc. (CTOR) reported interest expense of $33.03K in Q1 2026.

What does interest expense mean?

Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Delcath SystemsDCTH

$787K+27.3%

Arcus BiosciencesRCUS

$3M+200%

ImmunityBio, Inc.IBRX

$13.87M+2.5%

Gilead SciencesGILD

$240M-7.7%

United TherapeuticsUTHR

$3M-50.8%

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s interest expense?: Citius Oncology, Inc. (CTOR) reported interest expense of $33.03K in Q1 2026.
What does interest expense mean?: Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.